Colm Burke (Fine Gael) | Oireachtas source

This Adjournment matter concerns the drug Fampyra which is used by multiple sclerosis patients. It has been brought to my attention by a patient using the drug on a trial basis with positive effects that it is not covered by the GMS or drugs payment scheme. The patient's consultant, Dr. Brian Sweeney in Cork, has recommended that she continue using the drug, but it is costing her approximately €250 per month. She does not qualify for a refund and the expense is causing her problems. The advantage of the drug is that it improves mobility and reduces fatigue, although it does not work for everyone. That said, it works for a large number of patients and many consultants have recommended its use. It is recognised in many other European countries and I ask the Minister to consider recognising it here, too, in the GMS, the long-term illness scheme and the drugs payment scheme.